Is the latest Alzheimer’s drug for real? Is three a crowd in CAR-T? And what’s a Bionomy?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, medicinal chemist Derek Lowe joins us to discuss China’s surprising decision to approve a new treatment for Alzheimer’s disease — and why the resulting hope quickly turned to skepticism among experts. Then, we preview an all-important FDA meeting about Amarin and it’s fish-oil-derived cardiovascular drug. Later, we talk about how Celgene might find itself on the outside looking in when it comes to CAR-T cancer therapy. Finally, in honor of STAT’s fourth birthday, executive editor Rick Berke joins us to discuss the publication’s origins and where it’s headed.